NCT06473909View on ClinicalTrials.gov

Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Acute Graft Versus Host Disease

Interventions

DRUG

CD25 antibody combined glucocorticoid as first-line treatment

CD25 antibody combined glucocorticoid as first-line treatment

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER